Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VTP-43742 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Dose-matched placebo administered as oral capsule(s) once daily |
| VTP-43742 Dose 1 | EXPERIMENTAL | VTP-43742 administered as oral capsule(s) once daily |
| VTP-43742 Dose 2 | EXPERIMENTAL | VTP-43742 administered as oral capsule(s) once daily |
| VTP-43742 Dose 3 | EXPERIMENTAL | VTP-43742 administered as oral capsule(s) once daily |
| VTP-43742 Dose 4 | EXPERIMENTAL | VTP-43742 administered as oral capsule(s) once daily |
| VTP-43742 Dose 5 | EXPERIMENTAL | VTP-43742 administered as oral capsule(s) once daily |
| Placebo 1 | PLACEBO_COMPARATOR | healthy volunteers |
| VTP-43742 Dose 6 | EXPERIMENTAL | healthy volunteers |
| VTP-43742 Dose 7 | EXPERIMENTAL | healthy volunteers |
| Placebo 2 | PLACEBO_COMPARATOR | psoriatic patients |
| VTP-43742 Dose 8 | EXPERIMENTAL | psoriatic patients |
| VTP-43742 Dose 9 | EXPERIMENTAL | psoriatic patients |
| VTP-43742 Dose 10 | EXPERIMENTAL | psoriatic patients |
| VTP-43742 Dose 11 | EXPERIMENTAL | psoriatic patients |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Dose-matched placebo administered as oral capsule(s) once daily |
| VTP-43742 | DRUG | VTP-43742 administered as oral capsule(s) once daily |
| Placebo 1 | DRUG | Placebo 1 matching VTP-43742 administered as an oral capsule once daily |
| Placebo 2 | DRUG | Placebo 2 matching VTP-43742 administered as an oral capsule once daily |
Inclusion Criteria: * Healthy males or females, 18 to 45 years of age, inclusive. * Body weight of at least 55 kg and body mass index of 18-32 kg/m2, inclusive. * Medically healthy with clinically insignificant screening results. * Women of child-bearing potential (WOCBP) AND men with partners who ...
VTP-43742 is an investigational small molecule being developed for the treatment of psoriasis. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being studied in clinical trials that include healthy volunteers and psoriatic patients.
VTP-43742 is being developed by Syndax Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SNDX. The company is conducting clinical trials for this investigational drug in the United States.
VTP-43742 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 trials have been completed, both of which were randomized, double-blind, and placebo-controlled studies.
VTP-43742 has been studied in two completed Phase 1 clinical trials. The first, NCT02555709, enrolled 74 participants and included healthy volunteers and psoriatic patients. The second, NCT03724292, enrolled 40 healthy volunteers. Both trials were conducted in the United States.
No alternative names for VTP-43742 have been disclosed. The drug is referred to by its code name VTP-43742 in clinical trial registries and by its developer, Syndax Pharmaceuticals.